Mini ReviewHuman Interferons Alpha, Beta and Omega

@article{Bekisz2004MiniRI,
  title={Mini ReviewHuman Interferons Alpha, Beta and Omega},
  author={Joseph Bekisz and Hana Schmeisser and Jessica Hernandez and Neil D. Goldman and Kathryn C Zoon},
  journal={Growth Factors},
  year={2004},
  volume={22},
  pages={243 - 251}
}
Type I interferons (IFNs), IFN-α, IFN-β, IFN-ω, IFN-δ and IFN-τ are a family of structurally related, species-specific proteins found only in vertebrates. They exhibit a variety of biological functions, including antiviral, antiproliferative, immunomodulatory and developmental activities. Human Type I IFNs interact with the human IFN alpha receptor (IFNAR), which is composed of two identified subunits (IFNAR-1 and IFNAR-2). The interaction of IFN-α/β with its receptor components results in the… 
View on Taylor & Francis
zenodo.org
94 Citations
Highly Influential Citations
2
Background Citations
22

94 Citations

Type I interferons: ancient peptides with still under-discovered anti-cancer properties.

Current knowledge about the antitumor activity of type I IFNs is reviews the current knowledge, focusing on new potential strategies able to strengthen the antitalpine activity of these cytokines.

Type I interferons as vaccine adjuvants against infectious diseases and cancer

Recent studies in humans and in animal models are summarized, suggesting a possible application of type I IFNs as adjuvants for the development of more effective vaccines against infectious diseases and cancer.

Effect of Type-I Interferon on Retroviruses

Type-I interferons (IFN-I) play an important role in the innate immune response to several retroviruses. They seem to be effective in controlling the in vivo infection, though many of the clinical…

Clinical Significance of Serum Type III Interferons in Patients with Gastric Cancer.

  • Hua ZhaoNan Dong X. Ren
  • Biology, Medicine
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 2019
High serum IFN-λ2/3 levels were associated with poor prognosis and could be a novel biomarker for evaluating GC progression and predicting the outcomes of nonmetastatic GC.

Bovine Interferon Lambda Is a Potent Antiviral Against SARS-CoV-2 Infection in vitro

Results show that rbIFN-λ is as an effective antiviral potentially suitable for COVID-19 therapy, and due to the non-specific activity of this IFN, it can be potentially effective against other respiratory viruses that may be circulating together with SARS-CoV-2.

Interferon modulates central nervous system function

Second-Generation Interferons: An Effective, Long-Lasting Hyperglycosylated IFN-alpha2

This newly designed and long-acting IFN analog confirmed that glycoengineering represents a proper strategy for increasing the in vivo activity of naturally non N-glycosylated proteins, leading to a novel drug that might combine less administration frequency with improved therapeutic efficacy.

Development and characterization of type I interferon receptor knockout sheep: A model for viral immunology and reproductive signaling

Historical data supports the concept that ruminants utilize a novel type I IFN, IFN-tau, for pregnancy recognition, making IFNAR knockout sheep a valuable model for studying pregnancy recognition.

Expression Pattern of Individual IFNA Subtypes in Chronic HIV Infection

The expression profiles of all IFN-α subtypes in treated and treatment-naive HIV+ patients and their impact on the induction of distinct HIV restriction factors were determined.

RETRACTED: Effects of recombinant type I interferon therapy on human muscle diseases

The immunomodulating effects of IFNβ therapy showed no clinically significant benefit during prospective controlled treatment trials of inclusion body myositis, and the mechanisms through which type I IFNs induce autoimmunity are incompletely understood.
...

References

SHOWING 1-10 OF 40 REFERENCES

Review: IFN-α/β Receptor Interactions to Biologic Outcomes: Understanding the Circuitry

The intent of this review is to place these signaling cascades and their effectors in the context of distinct biologic outcomes.

Differences in Interferon α and β Signaling

The data demonstrate that the signaling specificity for different Type I IFNs is established early in the signaling cascade, at the receptor level, and results from distinct interactions between components of the Type IIFNR.

Interferon-delta: the first member of a novel type I interferon family.

Human type I interferon receptor, IFNAR, is a heavily glycosylated 120-130 kD membrane protein.

Variations in the mean value and the range of molecular mass between IFNAR in different cell lines suggest differences in glycosylation, although there may also be a small amount O-linked oligosaccharide.

Signal transduction by type I interferons.

Advances made in elucidating the molecular events that mediate the biological responses to type I interferons are summarized.

The Short Form of the Interferon α/β Receptor Chain 2 Acts as a Dominant Negative for Type I Interferon Action*

It is shown that IFNα8 and IFNβ1b induce antiviral and antiproliferative activity in mouse cell transfectants expressing the human IFNAR1 chain of the receptor and induce the formation of STAT1/STAT2 dimers in IFN-stimulated response element (ISRE)-dependent gel shift assays.

Intrinsic ligand binding properties of the human and bovine alpha-interferon receptors.

The intrinsic ligand binding properties of the bovine and human IFN-alpha R1 polypeptides expressed in Xenopus laevis oocytes show significant binding and formation of crosslinked complexes with human IFn-alpha A and IFW-alpha B.

The human interferon α β receptor: Characterization and molecular cloning

The interferon-α/β system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors

Interferon-α / β-Receptor Interactions: A Complex Story Unfolding

This review focuses on IFN-receptor interactions, the key residues involved in this interaction and the potential for targeted modifications of the ligand to enhance bioactivity.